{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:33:57Z","timestamp":1794576837864,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.psychres.2025.116821","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:13:24Z","timestamp":1762272804000},"page":"116821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression"],"prefix":"10.1016","volume":"354","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-4503","authenticated-orcid":false,"given":"Ahmed Z","family":"Elmaadawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Naha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2492","authenticated-orcid":false,"given":"Shruti","family":"Prabhudesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Eltohamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2025.116821_bib0002","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord"},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0003","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert. Opin. Drug. Saf."},{"key":"10.1016\/j.psychres.2025.116821_bib0004","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neubiorev.2017.03.010","article-title":"Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis","volume":"77","author":"Bartoli","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2025.116821_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114579","article-title":"Sex differences in ketamine's therapeutic effects for mood disorders: a systematic review","volume":"312","author":"Benitah","year":"2022","journal-title":"Psychiatry. Res."},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/0706743719828965","article-title":"Current and Common Definitions of Treatment-Resistant Depression: findings from a Systematic Review and Qualitative Interviews","volume":"64","author":"Brown","year":"2019","journal-title":"Can. J. Psychiatry."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0007","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/EDE.0000000000000639","article-title":"Instrumental Variable Analyses and Selection Bias","volume":"28","author":"Canan","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.psychres.2025.116821_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2022.07.054","article-title":"The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder","volume":"315","author":"Chen","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.psychres.2025.116821_bib0009","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: a Randomized Clinical Trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiat."},{"issue":"11","key":"10.1016\/j.psychres.2025.116821_bib0011","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/da.23193","article-title":"The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder","volume":"38","author":"Daly","year":"2021","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.psychres.2025.116821_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan","year":"2023","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine Assisted Psychotherapy (KAP): patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoact. Drug."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0014","doi-asserted-by":"crossref","first-page":"c214","DOI":"10.1159\/000235241","article-title":"Cohort studies: prospective versus retrospective","volume":"113","author":"Euser","year":"2009","journal-title":"Nephron Clin. Pract."},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am. J. Psychiat."},{"issue":"7","key":"10.1016\/j.psychres.2025.116821_bib0016","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41386-023-01540-4","article-title":"A pilot randomized controlled trial of ketamine in Borderline Personality Disorder","volume":"48","author":"Fineberg","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/HRP.0000000000000185","article-title":"Functional Neuroanatomy of Emotion and Its Regulation in PTSD","volume":"26","author":"Fitzgerald","year":"2018","journal-title":"Harv. Rev. Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116821_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/biostatistics\/kxn010","article-title":"Adjusting for selection bias in retrospective, case-control studies","volume":"10","author":"Geneletti","year":"2009","journal-title":"Biostatistics"},{"issue":"5","key":"10.1016\/j.psychres.2025.116821_bib0019","doi-asserted-by":"crossref","DOI":"10.2196\/34711","article-title":"Efficacy and Tolerability of Two Novel \"Standard of Care\" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: protocol for a Pilot Observational Study","volume":"11","author":"Gutierrez","year":"2022","journal-title":"JMIR Res. Protoc."},{"key":"10.1016\/j.psychres.2025.116821_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bcp.2018.03.032","article-title":"Ketamine and ketamine metabolites as novel estrogen receptor ligands: induction of cytochrome P450 and AMPA glutamate receptor gene expression","volume":"152","author":"Ho","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2025.116821_bib0022","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1002\/hup.2836","article-title":"Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression","volume":"37","author":"Jesus-Nunes","year":"2022","journal-title":"Hum. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.15m10381","article-title":"A New Prediction Model for Evaluating Treatment-Resistant Depression","volume":"78","author":"Kautzky","year":"2017","journal-title":"J. Clin. Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116821_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41398-021-01268-z","article-title":"Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers","volume":"11","author":"Kruse","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"49","key":"10.1016\/j.psychres.2025.116821_bib0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305772120","article-title":"Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments","volume":"120","author":"Krystal","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0026","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4097\/kja.19049","article-title":"Randomization in clinical studies","volume":"72","author":"Lim","year":"2019","journal-title":"Korean J. Anesthesiol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-021-03216-8","article-title":"Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses","volume":"78","author":"Lima","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116821_bib0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/EDE.0000000000001516","article-title":"Toward a Clearer Definition of Selection Bias When Estimating Causal Effects","volume":"33","author":"Lu","year":"2022","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0029","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira","year":"2009","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.psychres.2025.116821_bib0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0031","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s12325-021-01732-8","article-title":"Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression","volume":"38","author":"McMullen","year":"2021","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.psychres.2025.116821_bib0032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","article-title":"Use of Ketamine in Elderly Patients with Treatment-Resistant Depression","volume":"19","author":"Medeiros da Frota Ribeiro","year":"2017","journal-title":"Curr. Psychiat. Rep."},{"issue":"1","key":"10.1016\/j.psychres.2025.116821_bib0033","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41398-024-03180-8","article-title":"Personalized use of ketamine and esketamine for treatment-resistant depression","volume":"14","author":"Medeiros","year":"2024","journal-title":"Transl. Psychiat."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08039488.2021.1952303","article-title":"Treatment of difficult-to-treat depression - clinical guideline for selected interventions","volume":"76","author":"Moeller","year":"2022","journal-title":"Nord. J. Psychiat."},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin. Drug. Saf."},{"issue":"13","key":"10.1016\/j.psychres.2025.116821_bib0036","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41386-021-01104-4","article-title":"Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence","volume":"46","author":"Norbury","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2025.116821_bib0037","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41398-024-03033-4","article-title":"Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study","volume":"14","author":"Pan","year":"2024","journal-title":"Transl. Psychiat."},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0038","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: a Randomized Double-Blind Active-Controlled Study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiat."},{"issue":"3","key":"10.1016\/j.psychres.2025.116821_bib0039","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41380-023-02366-8","article-title":"Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis","volume":"29","author":"Rhee","year":"2024","journal-title":"Mol. Psychiat."},{"issue":"12","key":"10.1016\/j.psychres.2025.116821_bib0040","first-page":"1353","article-title":"The translational neural circuitry of anxiety","volume":"90","author":"Robinson","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"10.1016\/j.psychres.2025.116821_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1325399","article-title":"Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis","volume":"15","author":"Rodolico","year":"2024","journal-title":"Front Psychiat."},{"issue":"4","key":"10.1016\/j.psychres.2025.116821_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder","volume":"15","author":"Rong","year":"2018","journal-title":"Int. J. Environ. Res. Public Health."},{"issue":"11","key":"10.1016\/j.psychres.2025.116821_bib0043","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiat."},{"issue":"Pt A","key":"10.1016\/j.psychres.2025.116821_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuroimage.2015.08.070","article-title":"Effects of ketamine on cognition-emotion interaction in the brain","volume":"124","author":"Scheidegger","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.psychres.2025.116821_bib0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2025.116821_bib0046","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/npp.2009.83","article-title":"The neurocircuitry of fear, stress, and anxiety disorders","volume":"35","author":"Shin","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2025.116821_bib0047","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: an Observational Study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry."},{"issue":"Supplement I","key":"10.1016\/j.psychres.2025.116821_bib0048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.22365\/jpsych.2021.046","article-title":"The burden and the challenge of treatment-resistant depression","volume":"32","author":"Touloumis","year":"2021","journal-title":"Psychiatriki"},{"key":"10.1016\/j.psychres.2025.116821_bib0049","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2022.01.024","article-title":"Glutamatergic receptor and neuroplasticity in depression: implications for ketamine and rapastinel as the rapid-acting antidepressants","volume":"594","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.psychres.2025.116821_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry. Rep."},{"key":"10.1016\/j.psychres.2025.116821_bib0051","article-title":"Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?","volume":"15","author":"Wiedlocha","year":"2024","journal-title":"Front Psychiat."},{"issue":"4","key":"10.1016\/j.psychres.2025.116821_bib0052","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry."},{"issue":"4","key":"10.1016\/j.psychres.2025.116821_bib0053","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiat."},{"issue":"8","key":"10.1016\/j.psychres.2025.116821_bib0054","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen. Psychiat."},{"key":"10.1016\/j.psychres.2025.116821_bib0055","article-title":"Gender differences in the antianhedonic effects of repeated ketamine infusions in patients with depression","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Psychiat."},{"key":"10.1016\/j.psychres.2025.116821_bib0056","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2020.01.001","article-title":"Predictors of response to repeated ketamine infusions in depression with suicidal ideation: an ROC curve analysis","volume":"264","author":"Zhou","year":"2020","journal-title":"J. Affect. Disord."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125004664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125004664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:25:40Z","timestamp":1775049940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125004664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"alternative-id":["S0165178125004664"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116821","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116821"}}